Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Novavax Booster in Adults 18-49 (Study 312)
NCT05875701Phase 3Completed
- Sponsor
- Novavax
- Start
- Mar 2023
- Primary completion
- Nov 2023
- Modality
- Recombinant Proteins and Enzymes, Nanoparticles, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of NVX-CoV2373 in coronavirus disease 2019 (COVID-19), sponsored by Novavax. Started Mar 2023; status: completed.
02
Drugs
NVX-CoV2373
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05875701.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05875701.